Krystal Biotech, Inc. announced positive topline results from its Phase 2 trial of KB-301 for Netherton syndrome, a rare and severe genetic skin disorder. The study met its primary and secondary endpoints, with significant improvements in skin integrity and a favorable safety profile.
The company plans to engage with regulatory authorities to discuss next steps for the therapy.
Krystal Biotech shares surged in pre-market trading after the announcement. Analysts highlighted the potential for KB-301 to become the first approved treatment for Netherton syndrome and a major commercial opportunity for the company.